We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current SBLOF market cap is 408.83M. The company's latest EPS is JPY 132.8609 and P/E is 0.07.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 14.56B | 15.11B | 17.75B | 25.09B | 26.45B |
| Operating Income | 3.07B | 2.74B | 5.79B | 7.69B | 6.88B |
| Net Income | 2.55B | 3.66B | 7.13B | 6.06B | 5.53B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 39B | 36.97B | 39.31B | 57.24B | 76.3B |
| Total Liabilities | 22.62B | 21.13B | 19.59B | 30.88B | 42.14B |
| Total Equity | 16.38B | 15.84B | 19.72B | 26.36B | 34.16B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 3.02B | 4.75B | 5.95B | 4B | 2.11B |
| Investing | -1.46B | -268.66M | -4.27B | -5.93B | -6.91B |
| Financing | -1.45B | -2.47B | -4.91B | 6.27B | 5.32B |
| Market Cap | 408.83M |
| Price to Earnings Ratio | 0.07 |
| Price to Sales Ratio | 0.02 |
| Price to Cash Ratio | 0.04 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | 30,963.54% |
| Shares Outstanding | 41.63M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -42.13% |
| 52 Week High | 16.97 |
| 52 Week Low | 9.82 |
| Spread (Intraday) | 2.74 (22.74%) |
| Company Name | Shin Nippon Biomedical Laboratories Ltd (PK) |
| Address |
akashi-cho 8-1 chuo, tokyo 104-0044 |
| Website | https://www.snbl.com |
| Industry | chemicals diversified (B1) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
